Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
06:43pm, Wednesday, 16'th Oct 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024
3 MedTech Stocks to Buy as Monetary Policy Eases
12:55pm, Monday, 30'th Sep 2024
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte
06:25am, Monday, 16'th Sep 2024
Chicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical ISRG, Masimo Corp. MASI and Veracyte, Inc. VCYT.
3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost
12:06pm, Friday, 13'th Sep 2024
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and s
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
08:30am, Monday, 09'th Sep 2024
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
12:35pm, Thursday, 05'th Sep 2024
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
10:57am, Wednesday, 04'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Relative Price Strength Stocks That You Should Buy Now
09:01am, Friday, 30'th Aug 2024
SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
05:30pm, Monday, 26'th Aug 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
09:00am, Monday, 26'th Aug 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte is Named a Greater Bay Area Top Workplace by the San Francisco Chronicle.
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Monday, 19'th Aug 2024
After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 15'th Aug 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 14'th Aug 2024
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
10:10am, Thursday, 08'th Aug 2024
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
02:08pm, Wednesday, 07'th Aug 2024
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
